Harvard Bioscience
HBIO
Harvard Bioscience (HBIO) news
Recent news
Harvard Bioscience Q2 adjusted EPS USD -0.14
AInvest Wire · Aug 11, 2026Harvard Bioscience Inc outlook FY 2026 revenue growth between 3% and 5%
Harvard Bioscience Inc. has outlined an expected revenue growth range of 3% to 5% for fiscal year 2026, reflecting a measured approach to expansion amid evolving market conditions. The company’s first-quarter 2026 financial results, recently disclosed, provide early insight into its performance…
AInvest Wire · Aug 11, 2026Harvard Bioscience outlook FY gross margin 57-59%
AInvest Wire · Aug 11, 2026Harvard Bioscience expects overall run rate savings of ~$4M beginning in Q2 2024; expects Q2 restructuring-related charges of ~$0.5M
AInvest Wire · Apr 9, 2024Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate
AInvest Wire · Mar 7, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.